Emerging Blood-Based Biochemical Biomarkers in Alzheimer’s Disease: Advances in Early Detection and Disease Monitoring

Authors

  • Rahma Salim Abdullah Department of Chemistry, College of Education For women, University of Anbar, Ramadi Iraq

Keywords:

Alzheimer’s disease, Amyloid-beta, Blood biomarkers, GFAP, Neurofilament light, Phosphorylated tau

Abstract

Alzheimer's disease is now a biological phenomenon which has driven the need for scalable biomarkers to detect amyloid and tau pathology, and to measure disease activity during treatment. This review aims to assess the potential of the new blood-based biochemical markers along the Alzheimer continuum, with a special focus on the plasma amyloid-beta ratio, phosphorylated tau isoforms, glial fibrillary acidic protein, neurofilament light, brain-derived tau, inflammatory proteins, and multiplex proteomic signatures. Studies published between 2020 and September 2026 in PubMed were prioritized with some of the earlier influential studies for validation. Currently, plasma phosphorylated tau (p-tau) most generally discriminates Alzheimer-pathology, and p-tau217 can rival cerebrospinal-fluid testing when evaluated using validated platforms. Glial fibrillary acidic protein provides biological specificity and identifies early activation of the astrocytes, and neurofilament light provides nonspecific information on neuroaxonal injury, but is vulnerable to small analytical changes. Validation of tau and p-tau212/p-tau231 is needed in a larger head-to-head validation to enhance the staging. Use of these complementary biomarkers, in combination with other factors such as age, cognition, APOE genotype and clinical context, can enhance the accuracy of triage; but accuracy of triage is dependent on the assay, cut-off strategy, disease prevalence, renal function, BMI, ethnicity and comorbidity. Although the use of longitudinal biomarker change is suggested as a tool for monitoring treatment, thresholds that are clinically relevant for individual patients are not known. Before implementation, it is crucial to have standardized preanalytics, certified reference materials, external quality assessment, transparent reporting, and diversity of prospective cohorts. Blood biomarkers are not meant to be a substitute for clinical evaluation and confirmatory CSF or PET testing, but rather should be used in conjunction with these two other tests when the results are intermediate, discordant, or when there is risk of treatment decisions. The first thing they have to offer is easy-to-navigate rule-out and referral options, trial enrichment, and biologically-driven monitoring on the ground.

Downloads

Published

2026-11-15

Issue

Section

Articles

How to Cite

1.
Rahma Salim Abdullah. Emerging Blood-Based Biochemical Biomarkers in Alzheimer’s Disease: Advances in Early Detection and Disease Monitoring. Sawa Med. J. [Internet]. 2026 Nov. 15 [cited 2026 Nov. 17];2(4):981-1007. Available from: https://smj.sawauniversity.edu.iq/article/view/909